These results shoved a lower expression of PD-L1 than in the studies by Alaghehbandan et al. and Mitsuko et al.; however, a recent comprehensive molecular analysis of papillary renal cell carcinomas demonstrated that type 2 papillary renal cell carcinomas consist of multiple distinct subgroups differing in molecular and phenotypic features, characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2-ARE pathway, whereas type 1 papillary renal cell carcinoma is associated with MET alterations [103]. The gene discussed is CD274; the disease is papillary renal cell carcinoma.